Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2010
10/26/2010US7820627 with core structure of pentaerythritol used as replacement for sugars; immunomodulators; immunogens within liposomes; tumor antigens; for use as haptens, inhibitors of bacterial-host cell adhesion; septic shock
10/26/2010US7820621 also targeting tumor cells that express vascular endothelial growth factor neuropilin-1 receptor; radiotherapy; radiopharmaceuticals; treating angiogenesis
10/26/2010US7820447 drug screening; for carcinomas, especially lymphoma carcinomas
10/26/2010US7820440 Using vector comprising early gene modifications as genetic transfer element in gene therapy; gnentic vaccines
10/26/2010US7820410 Proteins with high immunoreactivity and method for their production
10/26/2010US7820400 Tumor-associated marker
10/26/2010US7820375 Use of a protein of the CRMP family for treating diseases related to the immune system
10/26/2010US7820193 Anticancer agents; prevent forming blood vessels; removal blockage
10/26/2010US7820178 VEGF isoforms and their use as anti-angiogenic, anti-vasodilatory, anti-permeability and anti-proliferative agents
10/26/2010US7820170 monoclonal antibody exhibit antagonist activity of the anti-CD40 antibody; antiproliferative agents; controlling cell differentiation; anticarcinogenic agents; Hodgkin's disease, leukemias
10/26/2010US7820169 inhibiting the activity of tumor necrosis factor TNF in a patient having rheumatoid arthritis or psoriatic arthritis, by administering a composition comprising an effective amount of human anti-TNF antibody comprising a heavy chain variable region comprising SEQ ID NO:7 and a light chain variable
10/26/2010US7820161 Treatment of autoimmune diseases
10/26/2010US7820143 Water soluble tetrapyrollic photosensitizers for photodynamic therapy
10/26/2010CA2579391C Anti-a33 antibody
10/26/2010CA2543650C A crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing thesame
10/26/2010CA2511446C Synthetic peptide analogs for the treatment of cancer
10/26/2010CA2449192C Novel nitriles useful as reversible inhibitors of cysteine proteases
10/26/2010CA2443840C Cripto blocking antibodies and uses thereof
10/26/2010CA2434608C Promoting cell regeneration and/or cell differentiation with non-metabolizable sugar and a polymeric absorbent
10/26/2010CA2372058C Hemisynthetic method of ecteinascidins and new intermediates
10/26/2010CA2351887C Psca: prostate stem cell antigen and uses thereof
10/26/2010CA2330639C Method for producing a specific antiserum against the universal tumorous antigen and method for diagnosing malignant tumours using said antiserum
10/26/2010CA2327349C Il-2 selective agonists and antagonists
10/26/2010CA2135591C Stabilized oligonucleotides and their use
10/21/2010WO2010121226A2 Anticancer agents
10/21/2010WO2010121225A2 Method of treating disorders associated with protein kinase ck2 activity
10/21/2010WO2010121180A1 Combination immunotherapy compositions against cancer and methods
10/21/2010WO2010121177A2 Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses
10/21/2010WO2010121175A1 Combination targeted therapy for lung cancer
10/21/2010WO2010121164A2 1,4-benzodiazepinone compounds and their use in treating cancer
10/21/2010WO2010120998A1 Pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
10/21/2010WO2010120996A1 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
10/21/2010WO2010120991A1 5, 6, 7, 8-tetrahydropyrido[4,3-d]pyrimidine compounds, their use as mtor, pi3, and hsmg-1 kinase inhibitors, and their syntheses
10/21/2010WO2010120987A1 Ring fused, ureidoaryl- and carbamoylaryl-bridged morpholino-pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
10/21/2010WO2010120966A1 Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
10/21/2010WO2010120942A2 Histone modification patterns for clinical diagnosis and prognosis of cancer
10/21/2010WO2010120872A2 Method of decreasing pro-adam10 secretase and/or beta secretase levels
10/21/2010WO2010120614A1 Benzodiazepine derivative for the treatment of hematopoietic neoplasm and leukemia
10/21/2010WO2010120561A1 Anti-fcrh5 antibodies and immunoconjugates and methods of use
10/21/2010WO2010120541A2 Compositions and methods for modulating the activity of complement regulatory proteins on target cells
10/21/2010WO2010120400A2 Substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carbonitriles and substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carboxamides as tubulin polymerization inhibitors
10/21/2010WO2010120374A2 Peptides targeting tnf family receptors and antagonizing tnf action, compositions, methods and uses thereof
10/21/2010WO2010120266A1 Hpv particles and uses thereof
10/21/2010WO2010120237A1 Imidazole substituted pyrimidines useful in the treatment of glycogen synthase kinase 3 related disorders such as alzheimer's disease
10/21/2010WO2010120121A2 Target-specific non-antibody protein and method for preparing the same
10/21/2010WO2010119991A2 Novel method of treating cancer
10/21/2010WO2010119875A1 Fused pyrrolopyridine derivative
10/21/2010WO2010119741A1 Preparation for external use
10/21/2010WO2010119698A1 Head-and-neck tumor proliferation inhibitor
10/21/2010WO2010119691A1 Diagnosis and treatment of cancer using anti-tmprss11e antibody
10/21/2010WO2010119583A1 Polymer-nucleic acid complex, method for imaging tumor cells or the like using same, and pharmaceutical composition for treatment of cancer
10/21/2010WO2010119285A1 Imidazo [1,2-a]pyridine derivatives as fgfr kinase inhibitors for use in therapy
10/21/2010WO2010119284A1 Bicyclic heterocyclyl derivatives as fgfr kinase inhibitors for therapeutic use
10/21/2010WO2010119264A1 Imidazopyrazines for use as kinase inhibitors
10/21/2010WO2010119194A1 Imidazolidine-2,4-dione derivatives and use thereof as a medicament
10/21/2010WO2010119193A1 Imidazolidine-2,4-dione derivatives, and use thereof as a cancer drug
10/21/2010WO2010119021A1 Tenascin-w and brain cancers
10/21/2010WO2010118986A1 Fluoro substituted pyrimidine compounds as jak3 inhibitors
10/21/2010WO2010118683A1 Targeted sustained-release microsphere of vascular occlusive agent containing sodium alginate and sorafenib, production method and use thereof
10/21/2010WO2010118675A1 New use of neferine
10/21/2010WO2010118598A1 Crystal form a of furanodiene, the preparation method and the useful for preparing the antitumor drug thereof
10/21/2010WO2010118524A1 Sensitizing agents for cancer therapy, methods of use and methods for the identification thereof
10/21/2010WO2010118522A1 Antibodies against prostate specific membrane antigen
10/21/2010WO2010118521A1 Peptide ligands for clusterin and uses thereof
10/21/2010WO2010099472A3 Spanx-b polypeptides and their use
10/21/2010WO2010099139A3 Combination of an either an anti-igf-ir- antibody or an igf binding protein and a small molecule igf-ir kinease inhibitor
10/21/2010WO2010097604A3 Guanidino-substituted bi- and polyphenyls as small molecule carriers
10/21/2010WO2010091892A3 Alkylamido compounds and uses thereof
10/21/2010WO2010091299A3 Combination of a 17 alpha-hydr0xylase/c17, 20-lyase inhibitor with an additional therapeutic agent
10/21/2010WO2010089327A3 Indole derivatives as anticancer agents
10/21/2010WO2010083154A3 Heterofunctional segment-poly(ethylene glycol) polymers as delivery vehicles
10/21/2010WO2010077589A3 Stat3 inhibitors and therapeutic methods using the same
10/21/2010WO2010076813A4 Thienopyridines as pharmacologically active agents
10/21/2010WO2010072740A3 TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
10/21/2010WO2010068947A3 Nuclear export inhibitors of topoisomerase ii alpha
10/21/2010WO2010068877A3 Compounds that bind oxysterol binding proteins, and methods of use thereof
10/21/2010WO2010066810A8 Transdermal pharmaceutical compositions comprising a serm
10/21/2010WO2010062742A3 Methods for freparation and use of marrow infiltrating lymphocytes (mils)
10/21/2010WO2010056985A3 Treatment of proteinopathies using a farnesyl transferase inhibitor
10/21/2010WO2010047509A3 Anti-dr5 antibody with improved affinity and stability, and composition for cancer prevention or treatment including same
10/21/2010WO2010042890A3 Polypeptides that bind trail-ri and trail-r2
10/21/2010WO2010008847A3 Pi3k/m tor inhibitors
10/21/2010WO2009126515A8 Compounds and compositions as protein kinase inhibitors
10/21/2010WO2009126514A8 Compounds and compositions as kinase inhibitors
10/21/2010WO2009110007A8 Spiro derivatives of parthenin as novel anticancer agents
10/21/2010WO2009100656A8 2-methylene-5-substituted methylene cyclopentanone derivatives and use thereof
10/21/2010WO2009096245A9 Pharmaceutical composition and combined agent
10/21/2010US20100269184 Apo-2DcR
10/21/2010US20100267824 Stable oxaliplatin composition for parenteral administration
10/21/2010US20100267822 Aurones as estrogen receptor modulators and their use in sex hormone dependent diseases
10/21/2010US20100267820 Antiadhesion agents
10/21/2010US20100267818 Stabilized single-liquid pharmaceutical composition containing docetaxel
10/21/2010US20100267814 Targeting MicroRNAs for the Treatment of Liver Cancer
10/21/2010US20100267808 Bispecific Antisense Oligonucleotides that Inhibit IGFBP-2 and IGFBP-5 and Methods of Using Same
10/21/2010US20100267806 LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
10/21/2010US20100267803 Regulators Of Fat Metabolism As Anti-Cancer Targets
10/21/2010US20100267802 Delivery method
10/21/2010US20100267801 Cyclohexyl sulphones for treatment of cancer
10/21/2010US20100267800 N-Alkyl-Hydroxamic Acid-Isoindolyl Compounds and Their Pharmaceutical Uses
10/21/2010US20100267793 Method of treatment using n3 alkylated benzimidazole derivatives as mek inhibitors
1 ... 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 ... 2211